Assenagon Asset Management S.A. Cyma Bay Therapeutics, Inc. Transaction History

Assenagon Asset Management S.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 17, 2024	BUY	$12.63 - $24.47 $9.43 Million - $18.3 Million	746,353 New	746,353 $17.6 Million
Q4 2019 Jan 17, 2020	SELL	$1.33 - $5.93 $269,363 - $1.2 Million	-202,529 Closed	0 $0
Q3 2019 Oct 16, 2019	BUY	$5.12 - $7.21 $1.04 Million - $1.46 Million	202,529 New	202,529 $1.04 Million

1.88M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.